Drug Profile
XL 228
Alternative Names: XL-228Latest Information Update: 09 Mar 2011
Price :
$50
*
At a glance
- Originator Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Insulin-like growth factor-I receptor antagonists; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 22 Feb 2011 XL 228 is available for collaborations or other external opportunities as of 22 Feb 2011. http://www.exelixis.com/
- 22 Feb 2011 Discontinued - Phase-I for Acute lymphoblastic leukaemia in USA (IV)
- 22 Feb 2011 Discontinued - Phase-I for Cancer in USA (IV)